SYS-MEL

SYSTEMS-BASED VIEW OF MELANOMA PROGRESSION: TOWARDS NOVEL DIAGNOSTIC (AND THERAPEUTIC) APPLICATIONS

 Coordinatore UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN 

 Organization address address: BELFIELD
city: DUBLIN
postcode: 4

contact info
Titolo: Mr.
Nome: Donal
Cognome: Doolan
Email: send email
Telefono: +353 17161656
Fax: +353 17161216

 Nazionalità Coordinatore Ireland [IE]
 Totale costo 1˙814˙000 €
 EC contributo 1˙814˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2013-IAPP
 Funding Scheme MC-IAPP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-11-01   -   2017-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

 Organization address address: BELFIELD
city: DUBLIN
postcode: 4

contact info
Titolo: Mr.
Nome: Donal
Cognome: Doolan
Email: send email
Telefono: +353 17161656
Fax: +353 17161216

IE (DUBLIN) coordinator 265˙186.11
2    OncoMark Limited

 Organization address address: Weston Park 76
city: DUBLIN 14
postcode: -

contact info
Titolo: Mr.
Nome: Stephen
Cognome: Penney
Email: send email
Telefono: +353 17163666
Fax: +3531 716 3709

IE (DUBLIN 14) participant 680˙573.73
3    PATHOLOGY DIAGNOSTICS LTD

 Organization address address: COWLEY ROAD ST JOHN S INNOVATION
city: CAMBRIDGE CAMBRIDGESHIRE
postcode: CB4 0WS

contact info
Titolo: Mr.
Nome: Vivian
Cognome: Bolton
Email: send email
Telefono: +44 1223 421334
Fax: +44 1223 420 844

UK (CAMBRIDGE CAMBRIDGESHIRE) participant 385˙051.04
4    ROYAL COLLEGE OF SURGEONS IN IRELAND

 Organization address address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2

contact info
Titolo: Dr.
Nome: Markus
Cognome: Rehm
Email: send email
Telefono: +353 14028563

IE (DUBLIN) participant 195˙052.48
5    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Ms.
Nome: Monique
Cognome: Vanhaeren
Email: send email
Telefono: +32 16 32 95 61
Fax: +32 16 32 65 15

BE (LEUVEN) participant 155˙980.00
6    The Beatson Institute for Cancer Research

 Organization address address: "GARSCUBE ESTATE, SWITCHBACK ROAD"
city: GLASGOW
postcode: G61 1BD

contact info
Titolo: Prof.
Nome: Owen
Cognome: Sansom
Email: send email
Telefono: +141 3303696

UK (GLASGOW) participant 132˙156.64

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

patient    responses    pathways    model    metastasis    computational    melanoma    progression    therapies    prognostic    disease    signalling    sys    incorporating    biomarkers    mel    epigenomic    biology    validate    predictive   

 Obiettivo del progetto (Objective)

'Worldwide figures show that there were 160,000 incidences of melanoma in 2002, whilst 39,000 died from the disease. These upward trends are worrying, as malignant melanoma is one of the most difficult cancers to treat, due to its ability to spread quickly and its resistance to standard chemotherapeutic agents. In order to counteract this trend, targeted therapies that inhibit melanoma metastasis are required. The aim of SYS-MEL is to identify and validate prognostic and predictive biomarkers for melanoma, and to model the predictive value of these biomarkers in determining the efficacy of melanoma therapies. The central objective is to bring together four European academic institutes and two SMEs to develop 3 prognostic/predictive biomarker assays for melanoma. 3 core areas of interest are epigenetics, signalling pathways in melanoma and systems biological approaches for predicting chemotherapy responses. SYS-MEL will have three main elements: 1) Epigenomic and protein expression analysis of melanoma tissue, to validate an epigenomic signature initially identified in the FP7-funded programme Target-Melanoma; 2) In silico modelling and prediction of patient responses to decarbazine DTIC using both in vitro analysis of apoptotic pathways and a novel systems biology approach, incorporating mathematical systems modelling, quantitative biochemistry and cell biology; 3) Investigating the components of the P-Rex1 pathway that are involved in driving the migration of melanoblast cells, and thus the progression of metastasis, incorporating a computational system tailored to model complex signalling pathways. This approach will enable us to identify prognostic and predictive biomarkers for melanoma, and to develop a powerful computational modeling approach to predict disease progression and patient responses to treatment.'

Altri progetti dello stesso programma (FP7-PEOPLE)

TRYPNUP (2012)

Nuclear envelope proteins of Trypanosoma brucei

Read More  

TRANZFOR (2009)

Transferring Research between EU and Australia-New Zealand on Forestry and Climate Change”

Read More  

MOREBRAIN (2008)

Brain Circulation - From Brain Drain to Brain Gain

Read More